What Is Dossier Due Diligence in the Context of INVIMA Registration?

Dossier due diligence is a term borrowed from financial practice, where it describes the process of evaluating an asset before committing a transaction. In pharmaceutical regulation, it means something more specific: a structured evaluation of a registration dossier to determine whether it is ready for a target regulatory agency's review, not just whether it is complete.

The distinction matters because completeness and readiness are not the same thing. A dossier can contain every required module, every expected data package, and every supporting document — and still generate observations, clarification requests, or extended review cycles when it meets an agency with a local interpretive framework.

In the context of INVIMA registration, dossier due diligence is the process of identifying those interpretation gaps before they become regulatory findings.

What the evaluation covers

A dossier due diligence assessment for Colombia evaluates the submission package against INVIMA's local regulatory logic — not only against the ICH M4 CTD standard or the framework of another agency that previously reviewed the product. The scope typically includes:

• Technical module coherence — whether the data across Module 3, 4, and 5 supports a consistent regulatory narrative when read under INVIMA's evaluation criteria
• Pharmacovigilance alignment — whether the PV system documentation reflects the obligations INVIMA expects from day one of registration
• Lifecycle management logic — whether the dossier anticipates how post-approval changes will be handled and documented in Colombia
• Local regulatory coherence — whether the submission reflects an understanding of INVIMA's administrative and technical requirements, not just international harmonization standards
• Manufacturing continuity — whether process documentation supports the level of consistency and traceability INVIMA evaluates across the product lifecycle

For complex products — particularly biologics — each of these dimensions carries additional interpretive weight. INVIMA's evaluation logic for biologics is more granular than for small molecule products, and the gaps that surface most frequently in review are not data gaps. They are coherence gaps.

When it is relevant

Dossier due diligence is most commonly associated with two scenarios. The first is pre-submission: a company preparing to register a product in Colombia evaluates the dossier before submitting, with the goal of identifying and resolving interpretation gaps before they generate observations during INVIMA's review.

The second is post-observation: a company that has already received clarification requests or findings from INVIMA uses the assessment to understand the structural origin of those observations — and to determine whether the gaps are isolated or systemic across the portfolio.

In both cases, the value of the assessment is not in confirming that the documentation exists. It is in evaluating whether the documentation makes the right regulatory argument for the market it is entering.

How it connects to regulatory strategy

Dossier due diligence is not a standalone service — it is an input into a regulatory strategy. The findings of an assessment inform submission timelines, clarification of response preparation, lifecycle planning, and in the case of portfolio entries, the sequencing of multiple registrations.

For global companies managing biologics or complex product portfolios across LATAM, the assessment also serves a portfolio function: identifying whether a structural assumption carried in one dossier template replicates across other assets in the pipeline, before those assets reach submission.

In Colombia specifically, where INVIMA's regulatory posture is becoming more structured and more interpretive, dossier due diligence has shifted from a risk mitigation step to a standard component of market entry preparation for complex products.

If you are preparing a dossier for INVIMA registration or evaluating observations received during review, a dossier due diligence assessment can help identify where the interpretation gaps are — and what it takes to close them. Freyr's regulatory teams in Colombia are available to discuss your specific situation.